Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136772 | 1.00 | NOS1 (0.43) | NOS1NOS3NOS2DGAT1 | |
| SCHEMBL12317214 | 1.00 | NOS1 (0.43) | NOS1NOS3NOS2DGAT1 | |
| SCHEMBL8812889 | 0.80 | DGAT1 (0.32) | NOS1NOS3NOS2DGAT1 | |
| SCHEMBL875384 | 0.80 | NOS1 (0.32) | NOS1NOS3NOS2 | |
| SCHEMBL320541 | 0.78 | DGAT1 (0.34) | NOS1NOS3NOS2DGAT1 | |
| SCHEMBL8974211 | 0.77 | DGAT1 (0.31) | NOS1NOS3NOS2DGAT1 | |
| SCHEMBL12146973 | 0.77 | DGAT1 (0.31) | NOS1NOS3NOS2DGAT1 | |
| SCHEMBL8134503 | 0.76 | — | — | |
| SCHEMBL17348031 | 0.76 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL11247187 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024032799-A1 | Preparation Method of Tetrodotoxin and its Analog | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-02-15 | — | — | WO | claimed |
| CN-113301926-A | Compounds targeting norepinephrine transporters | 广州市迈飞医学科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| WO-2011156355-A1 | PRODUCTION METHOD OF PHENYL GUANIDINE SALTS AND THEIR INTERMEDIATES | KAINOS MEDICINE, INC. (KR) | 2011-12-15 | — | — | WO | claimed |
| US-20060172927-A1 | Analogs of human growth hormone-releasing hormone, their preparation and use | INSTYTUT FARMACEUTYCZNY (PL) | 2006-08-03 | — | — | US | claimed |
| EP-3877439-B1 | ANALGESIC AND ANTI-ADDICTIVE COMPOSITIONS FOR TREATMENT OF CHRONIC PAIN AND OPIOID ADDICTION | UNIV MINNESOTA (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024032799-A1 | Preparation Method of Tetrodotoxin and its Analog | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-02-15 | — | — | WO | disclosed |
| CN-111757883-B | Novel inhibitors of bacterial glutaminyl cyclase for the treatment of periodontal disease and related diseases | 弗劳恩霍夫应用研究促进协会 | 2024-02-13 | — | — | CN | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-1999007685-A1 | ANTIBIOTIC FOR METHICILLIN RESISTANT BACTERIA | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1998005961-A1 | COMPOUNDS HAVING A PLURALITY OF NITROGENOUS SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997047194-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997030073-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-08-21 | — | — | WO | disclosed |
| EP-0789708-A1 | MULTIFUNCTIONAL MOLECULAR COMPLEXES FOR GENE TRANSFER TO CELLS | APOLLON, INC. (US) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | NOS1 3908/4885NOS3 3698/4885NOS2 3984/4885 |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | NOS1 3908/4885NOS3 3698/4885NOS2 3984/4885 |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | NOS1 3908/4885NOS3 3698/4885NOS2 3984/4885 |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | NOS1 3908/4885NOS3 3698/4885NOS2 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.